Pharma Focus Asia

Oragenics Enters into an Exclusive Global Licence Agreement with Inspirevax

Wednesday, March 01, 2023

Oragenics announced that the Company has entered into an exclusive global licence agreement with Inspirevax for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics’ lead intranasal COVID-19 vaccine candidate.

Under the exclusive licencing agreement, Oragenics will pursue the development of NT-CoV2-1 with Inspirevax’s novel BDX301 intranasal mucosal adjuvant. Additionally, the agreement provides a certain period of time for the companies to expand collaboration to pursue the development of additional intranasal vaccine candidates using Inspirevax’s adjuvants.

This agreement is an important milestone in expanding development opportunities for Oragenics and for company's strategic initiatives. This collaboration with experts of Inspirevax enables to pursue the development of novel intranasal vaccine candidates.

Intranasally delivered vaccines with BDX301 adjuvant have shown encouraging results in preclinical models for COVID-19 infections. This partnership with Oragenics’ ensures for the development of a potential novel intranasal vaccine candidate in the global fight against COVID-19 and infectious disease.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024